Literature DB >> 6957421

Pharmacokinetics of isotretinoin following a single oral dose.

K C Khoo, D Reik, W A Colburn.   

Abstract

A pharmacokinetic profile was developed following oral administration of a single 100-mg oral dose of isotretinoin to 12 normal male volunteers. Concentrations of isotretinoin and its isomer, tretinoin, were measured in blood samples from 12 subjects and in urine and fecal samples from three of the 12 subjects. Blood concentration-time data during a 72-hour sampling interval were variable and, in five of the 12 cases, showed pronounced secondary and tertiary concentration maxima which were consistent with the theory of enterohepatic circulation (EHC) of isotretinoin in man. In five of the 12 subjects, adequate fits of the data could not be obtained using classical bi- or triexponential equations but were successfully fitted using a recently developed recycling model. Maximum blood concentrations of isotretinoin ranged from 74 to 511 ng/ml and occurred between 1 and 4 hours after dosing. Secondary maxima generally occurred between 6 and 24 hours after dosing. The harmonic mean elimination half-life was approximately 20 hours. These findings suggest that steady-state blood concentrations should be observed within one week. Negligible amounts of unchanged isotretinoin were excreted in urine, whereas 53 to 74 per cent of the dose was recovered as intact isotretinoin in the feces. The amount of intact drug in the feces could reflect biliary excretion of the conjugate of isotretinoin that is deconjugated beyond the site where absorption may occur, as well as unabsorbed drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6957421     DOI: 10.1002/j.1552-4604.1982.tb02692.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

1.  The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions.

Authors:  James J Leyden; James Q Del Rosso; Eric W Baum
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

2.  Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man.

Authors:  W A Colburn; F M Vane; H J Shorter
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Pharmacokinetics of isotretinoin during repetitive dosing to patients.

Authors:  R K Brazzell; F M Vane; C W Ehmann; W A Colburn
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.

Authors:  F G Larsen; F Nielsen-Kudsk; P Jakobsen; K Weismann; K Kragballe
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 5.  Isotretinoin. A review of its pharmacological properties and therapeutic efficacy in acne and other skin disorders.

Authors:  A Ward; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of the retinoids.

Authors:  R W Lucek; W A Colburn
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

7.  Patterning of retinoic acid signaling and cell proliferation in the hippocampus.

Authors:  Timothy Goodman; James E Crandall; Sonia E Nanescu; Loredana Quadro; Kirsty Shearer; Alexander Ross; Peter McCaffery
Journal:  Hippocampus       Date:  2012-06-11       Impact factor: 3.899

8.  Pharmacokinetics and effects on plasma retinol concentrations of 13-cis-retinoic acid in melanoma patients.

Authors:  F Formelli; E Cavadini; L Mascheroni; F Belli; N Cascinelli
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Washout Period for Pregnancy Post Isotretinoin Therapy.

Authors:  Hina Jajoria; Venkataram Mysore
Journal:  Indian Dermatol Online J       Date:  2020-03-09

Review 10.  Mechanisms of Feedback Regulation of Vitamin A Metabolism.

Authors:  Catherine O'Connor; Parisa Varshosaz; Alexander R Moise
Journal:  Nutrients       Date:  2022-03-21       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.